Last reviewed · How we verify

IMI/REL FDC — Competitive Intelligence Brief

IMI/REL FDC (IMI/REL FDC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbapenem/beta-lactamase inhibitor combination. Area: Infectious Disease.

phase 3 Carbapenem/beta-lactamase inhibitor combination Bacterial cell wall (penicillin-binding proteins); serine beta-lactamases Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

IMI/REL FDC (IMI/REL FDC) — Merck Sharp & Dohme LLC. IMI/REL is a fixed-dose combination of imipenem (a carbapenem antibiotic) and relebactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IMI/REL FDC TARGET IMI/REL FDC Merck Sharp & Dohme LLC phase 3 Carbapenem/beta-lactamase inhibitor combination Bacterial cell wall (penicillin-binding proteins); serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbapenem/beta-lactamase inhibitor combination class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMI/REL FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/imi-rel-fdc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: